Physician profile
Jon Michael Maier
NPI 1528152238
$8,019.19
in general payments reported to CMS, 2019-2025
36 companies · $2,692 in 2025
The $2,692 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $242 · 2021: $126 · 2022: $666 · 2023: $1,376 · 2024: $2,237 · 2025: $2,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.87 |
| Education | $171.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,927.32 | 2019-2025 | |
| Janssen Biotech, INC. | $1,186.10 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $810.91 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.60 | 2019-2025 | Xifaxan, Relistor |
| Pfizer INC. | $411.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $367.97 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $307.15 | 2024-2025 | Omvoh |
| Celgene Corporation | $263.24 | 2022-2024 | Zeposia |
| Medtronic, INC. | $199.26 | 2022-2023 | Endoflip |
| Vivus LLC | $194.32 | 2022-2025 | Pancreaze |
| Gilead Sciences, INC. | $188.87 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $178.20 | 2019-2024 | Dificid, Recarbrio, Zerbaxa |
| Genzyme Corporation | $166.64 | 2022-2025 | |
| Qol Medical, LLC | $166.51 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $153.69 | 2023-2025 | Ibsrela |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.